Print

Synergy Pharmaceuticals Reports Third Quarter 2013 Financial Results  
11/13/2013 10:53:08 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the third quarter ended September 30, 2013.

Recent Developments

•On August 5, 2013, Synergy announced the results of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) covering its lead guanylate cyclase-C (GC-C) agonist, plecanatide, for the treatment of chronic idiopathic constipation (CIC).

Help employers find you! Check out all the jobs and post your resume.

//-->